Slingshot members are tracking this event:
FDA approves Novartis' (NVS) BLA for CAR-T drug candidate CTL019—treating pediatrics, young adults with refractory B-cell acute lymphoblastic leukemia—for Priority Review
Slingshot Insights Explained
Mar 29, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Acute Lymphoblastic Leukemia, Bla, Fda, Car-t, Ctl019, Priority Review